{"schema_version":"secwatch.filing_event.v1","accession":"0000849146-23-000103","form_type":"8-K","ticker":"LFVN","cik":"0000849146","company_name":"Lifevantage Corp","filed_at":"2023-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.782378+00:00","generated_at":"2026-06-11T03:13:36.647887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeVantage Q4 revenue up 6.4% to $54.2M; declares special $0.40 dividend; FY2024 EPS guide $0.52-0.62","bullets":["Q4 GAAP EPS $0.15 vs loss $0.11 YoY; adjusted EPS $0.17 vs $0.01; revenue $54.2M (+6.4% YoY).","Americas revenue +17.9% (U.S. +18.6%); APAC/Europe -16.0%; total active accounts fell 8.3% to 143K.","Declared special cash dividend of $0.40/share plus regular $0.035/share, payable Sep 22, 2023.","FY2024 guidance: revenue $216-226M, adjusted EBITDA $16-18M, adjusted EPS $0.52-0.62 (28% tax rate).","Strong balance sheet: $21.6M cash, no debt; FY2023 operating cash flow $6.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0000849146-23-000103","json":"https://secwatch.observer/filing/0000849146-23-000103.json","markdown":"https://secwatch.observer/filing/0000849146-23-000103.md","text":"https://secwatch.observer/filing/0000849146-23-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000103/0000849146-23-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000103/lfvn-20230828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T03:13:36.647887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c45acb75e0ead18fb95230ac7ad6a2b56c5fe49e","claim":"Lifevantage Corp reported fourth quarter ended June 30, 2023 results: revenue $54.2 million, net income $2.0 million, EPS $0.15 per diluted share.","evidence_excerpt":"optimal health processes, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2023. Fourth Quarter Fiscal 2023 Summary*: • Revenue of $54.2 million, an increase of 6.4% from the prior year period. Excluding the negative impact of foreign currency fluctuations, fourth quarter revenue was up approximately 7.8%; • Revenue in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000103/0000849146-23-000103-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended June 30, 2023"},{"label":"Revenue","value":"$54.2 million"},{"label":"Net income","value":"$2.0 million"},{"label":"EPS","value":"$0.15 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}